Keep REMS ed optional: AAFP

At an FDA public meeting on issues and challenges around risk evaluation and mitigation strategy (REMS), the AAFP urged the agency to keep REMS-specific CME for extended-release and long-acting opioids voluntary, reported AAFP News Now.

Ann Karty, MD, medical director of the AAFP division of CME, said a prescriber-education mandate could impact patient access to those drugs.

It could also create confusion for doctors who are licensed in multiple states.

“If you start adding more requirements… there is the potential that some will not participate,” Karty told AAFP News Now.
You must be a registered member of MMM to post a comment.

Email Newsletters

Specialty medicines continue to be a hot category, one in which spending has surged behind products that treat medicine's most complex diseases. This eBook lays out the needs and hurdles along the specialty drug pathway, explaining how stakeholders are working to get meds into patients' hands and ease their experience. Click here to download.